Unit

UNIT 23.9 Expanding Mouse Ventricular Cardiomyocytes Through GSK-3 Inhibition

  1. Jan W. Buikema1,2,3,
  2. Peter-Paul M. Zwetsloot1,3,
  3. Pieter A. Doevendans3,
  4. Joost P.G. Sluijter3,
  5. Ibrahim J. Domian1,2,4

Published Online: 2 DEC 2013

DOI: 10.1002/0471143030.cb2309s61

Current Protocols in Cell Biology

Current Protocols in Cell Biology

How to Cite

Buikema, J. W., Zwetsloot, P.-P. M., Doevendans, P. A., Sluijter, J. P. and Domian, I. J. 2013. Expanding Mouse Ventricular Cardiomyocytes Through GSK-3 Inhibition. Current Protocols in Cell Biology. 61:23.9:23.9.1–23.9.10.

Author Information

  1. 1

    Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts

  2. 2

    Harvard Medical School, Boston, Massachusetts

  3. 3

    Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands

  4. 4

    Harvard Stem Cell Institute, Cambridge, Massachusetts

Publication History

  1. Published Online: 2 DEC 2013

Abstract

Controlled proliferation of cardiomyocytes remains a major limitation in cell biology and one of the main underlying hurdles for true modern regenerative medicine. Here, a technique is described for robust expansion of early fetal-derived mouse ventricular cardiomyocytes on a platform usable for high-throughput molecular screening, tissue engineering and, potentially, in vivo translational experiments. This method provides a small-molecule approach to control proliferation or differentiation of early beating cardiomyocytes through modulation of the Wnt/β-catenin signaling pathway. Moreover, isolation and expansion of fetal cardiomyocytes takes less than 3 weeks, yields a relatively pure (∼70%) functional myogenic population, and is highly reproducible. Curr. Protoc. Cell Biol. 61:23.9.1-23.9.10. © 2013 by John Wiley & Sons, Inc.

Keywords:

  • cardiomyocyte proliferation;
  • differentiation;
  • isolation;
  • expansion;
  • GSK-3 inhibitor;
  • Wnt/β-catenin signaling